Androgen deprivation therapy (ADT) extends life for appropriately selected patients diagnosed with prostate cancer.¹ Level-1 evidence supports this survival benefit in a wide breadth of clinical scenarios, which leads to high rates of ADT use globally.² A complete understanding of the adverse effects of this therapy is paramount to permit informed decision making and patient selection. As a part of this effort, a body of literature developed that supported a potential association between ADT and adverse cognitive function.^3,4 Subsequently, two research articles were published that used an electronic medical record (EMR)–based informatics approach to support a link between ADT and dementia in large, multi-institutional analyses.^5,6 However, not all studies have supported this association.⁷ Given the widespread use and effectiveness of ADT, investigations that replicate and assess causality of an association between ADT and dementia are critical before changes in patient care are considered.

中文翻译：

---

雄激素剥夺治疗和痴呆：大数据时代的新机遇和挑战

雄激素剥夺疗法（ADT），用于诊断患有前列腺癌适当选择患者延长寿命。¹ Level-1证据在广泛的临床场景中支持这种生存优势，这导致全球范围内ADT的高使用率。²对这种疗法的不良影响的全面了解对于做出明智的决策和选择患者至关重要。作为这项工作的一部分，大量文献支持ADT与不良认知功能之间的潜在关联。^3,4随后，发表了两篇研究文章，这些文章使用了基于电子病历（EMR）的信息学方法来支持大型多机构分析中ADT与痴呆之间的联系。^5,6但是，并非所有研究都支持这种关联。⁷鉴于ADT的广泛使用和有效性，在考虑改变患者护理之前，复制和评估ADT与痴呆之间关联的因果关系的研究至关重要。